Case Report

Longitudinal Improvement of Neurocognition after Electroconvulsive Therapy in Bipolar Depression

Tomosuke Nakano, Eishi Motomura, Toshihiko Hasegawa, Yasuhiro Kawano, and Motohiro Okada

Department of Neuropsychiatry, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Japan

Correspondence should be addressed to Tomosuke Nakano; t-nakano@clin.med.mie-u.ac.jp

Received 21 April 2021; Revised 4 August 2021; Accepted 7 August 2021; Published 16 August 2021

Academic Editor: Yasuhiro Kaneda

Copyright © 2021 Tomosuke Nakano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Electroconvulsive therapy (ECT) is applied to treatment-resistant mood disorders. Its therapeutic effect on neurocognition remains unclear. We report the case of a 55-year-old man with treatment-resistant bipolar depression who underwent ECT series. We longitudinally monitored his neurocognition with the Brief Assessment of Cognition in Schizophrenia-Japanese version (BACS-J). The patient's scores on all of the BACS-J domains except working memory recovered after the ECT series. Interestingly, his verbal memory, motor speed, and executive function recovered 1 month after ECT, whereas his verbal fluency and attention scores recovered approx. 1 year after ECT. The BACS can be useful for monitoring ECT's longitudinal effects on individuals' cognitive recovery. Further studies with a large sample size are needed to confirm our present findings.

1. Introduction

Electroconvulsive therapy (ECT) is effective for the treatment of individuals with antidepressant-resistant major depression (for guidelines, see [1]) and those with mood stabilizer-resistant bipolar disorder [2]. Cognitive impairment is a clinically important treatment target, but the effects of ECT on neurocognition have been unclear. The Brief Assessment of Cognition in Schizophrenia (BACS) is designed to assess multiple aspects of neurocognitive functioning in individuals with schizophrenia [3]. Here, we describe the therapeutic effect of ECT on neurocognition evaluated by the BACS-J (Japanese version) [4] in a patient with treatment-resistant bipolar depression. Written informed consent for his case to be published was obtained from the patient.

2. Case Presentation

A 55-year-old man who had been treated with several antidepressants was admitted to our ward with a refractory depressive episode. At the first medical examination, he presented depressive mood, fatigue, and negative thoughts. He could not sit calmly, due to agitation. There was a familial history of depression in his brother. No psychiatric history was reported for him. During that admission, the patient presented accelerated speech with elevated mood, increasing energy, grandiosity, and irritability for several days. Based on the Diagnostic and Statistical Manual Disorders, 5th edition [5], he was rediagnosed with bipolar II disorder (DSM-5 code: 296.89). After this diagnosis, the patient's antidepressant treatment was switched to several mood stabilizers and antipsychotics, including quetiapine (300 mg/day) and valproate (1200 mg/day). However, his depressive mood and agitation did not improve sufficiently.

He gradually became exhausted due to his prolonged (>2-year) depression and then exhibited suicidal ideation. At his present admission, the results of blood tests, electroencephalography, and MRI were normal. To prevent his suicidal behavior, a total of 10 sessions of modified ECT (mECT) was carried out under anesthesia and muscle-relaxant medications. During the mECT course, quetiapine (300 mg/day) was continued, but valproate was discontinued. After the patient completed this mECT, his depressive symptoms improved considerably and suicidal thoughts
disappeared. He was treated with the daily maintenance medication of quetiapine 200 mg and valproate 600 mg (serum level 44.1 mg/L). His scores on both the Hamilton Rating Scale for Depression (HAM-D) and the BACS-J recovered (Figure 1(a)). At 1 month after the patient completed the mECT series, his scores on three domains of BACS-J (verbal memory, motor speed, and executive function) had recovered (Figure 1(b)). About 1 year after the mECT series, the patient’s scores on the remaining two domains of BACS-J (verbal fluency and attention and processing speed) showed delayed improvement; however, his working memory score had not improved.

He was discharged 2 months after the mECT series and was followed in outpatient settings. Along with the neurocognitive improvement, he achieved a recovery of depressive symptoms and daily/social function that allowed him to begin working again.

3. Discussion

To the best of our knowledge, this is the first reported case in which a patient’s cognitive improvement was longitudinally evaluated after mECT by using the BACS-J. A learning effect of the BACS-J used in this case has been described; Kaneda et al. [4] reported the good test-retest reliability of BACS-J by using two different versions within a short interval. We speculate that there is less possibility of a learning effect in our patient’s case because (1) the intervals between the assessment were >1 month and (2) two different versions of the BACS-J were administered alternatively in three sessions.

Several recent studies described after ECT improvements in patients’ cognitive function over long-term follow-up periods [6–8]. In our patient, compared to his scores on the BACS-J before the mECT series, the composite BACS-J score and the scores on all of the BACS-J domains except for working memory recovered along with his depressive symptoms after his treatment with mECT, which resulted in his social recovery. Interestingly, three domains improved immediately (verbal memory, motor speed, and executive function), but others improved later.

Anderson et al. [6] reported that patients with remission after mECT showed significant improvements in verbal fluency at 4 months after mECT compared to unremitting patients. However, our patient’s working memory deficits
persisted during a 1-year follow-up. A systematic review suggested that the working memory deficit persists even in remitted patients with bipolar disorder [9].

Several test batteries have been used after mECT cognitive assessments, including the Montreal Cognitive Assessment (MoCA), the Mini-Mental State Examination (MMSE), and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB). The MoCA and MMSE were developed as a tool to screen dementia patients. They can be easily administered within ≤10 min, whereas the disadvantage of these batteries is their "ceiling effect." In contrast, the MCCB was developed primarily for the assessment of neurocognition in individuals with schizophrenia disorders and has been widely used for other patients with psychiatric disorders. The administration of the MCCB takes ≥60 min. The BACS can be useful for longitudinally monitoring the neurocognition of patients treated with mECT, as it can be completed noninvasively within approx. 30 min and can monitor each domain of cognition separately.

In addition to these traditional cognitive properties, a focus on emotional characteristics of patients with mood disorders is needed. The Brief Assessment of Cognition in Affective Disorder (BAC-A) was developed as a comprehensive cognitive battery [10], but the suitability of the BAC-A for patients with bipolar depression remains to be explored. Moreover, the BAC-A has not been translated into Japanese. These are the reasons why we used the BACS-J in the present case.

Several studies revealed that there was no significant difference in cognition between patients in a euthymic or noneuthymic state [11, 12]; that is, unlike our patient’s case, the improvement of depressive symptoms is not associated with the improvement of cognition. In clinical settings, we should focus on the patients’ cognition as well as the severity of their illness. We propose that it is important to monitor longitudinal improvements of patients’ neurocognition after ECT.

Medications may also affect cognition. Indeed, quetiapine improves discriminability and the performance of a learning task, short-term task, and recognition tasks in patients with bipolar disorder [13, 14]. Valproate might have an adverse effect on cognition—especially working memory—in individuals with bipolar disorder [15]. Further studies with large sample sizes are also needed to clarify whether there is a difference in the effects of ECT and medications on cognition during long-term follow-up.

In conclusion, we have described the case of a patient with bipolar depression who showed longitudinal improvements in BACS-J scores along with a recovery of depressive symptoms after mECT. We speculate that the improvement in this patient’s neurocognition might have led to his positive prognosis.

Data Availability
The data used to support the findings of this study are included within the article.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this paper.

References
[1] G. S. Malhi, T. Outhred, A. Hamilton et al., “Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary,” The Medical Journal of Australia, vol. 208, no. 4, pp. 175–180, 2018.
[2] UK ECT Review Group, “Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis,” Lancet, vol. 361, no. 9360, pp. 799–808, 2003.
[3] R. S. Keefe, T. E. Goldberg, P. D. Harvey, J. M. Gold, M. P. Poe, and L. Coughenour, “The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery,” Schizophrenia Research, vol. 68, no. 2–3, pp. 283–297, 2004.
[4] Y. Kaneda, T. Sumiyoshi, R. Keefe, Y. Ishimoto, S. Numata, and T. Ohmori, “Brief assessment of cognition in schizophrenia: validation of the Japanese version,” Psychiatry and Clinical Neurosciences, vol. 61, no. 6, pp. 602–609, 2007.
[5] American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, D.C., 5th ed edition, 2013.
[6] I. M. Anderson, R. H. McAllister-Williams, D. Downey, R. Elliott, and C. Loo, “Cognitive function after electroconvulsive therapy for depression: relationship to clinical response,” Psychological Medicine, vol. 51, no. 10, pp. 1647–1656, 2021.
[7] K. Hebbrecht, E. J. Gilray, T. K. Birkenhäger et al., “Cognitive change after electroconvulsive therapy in mood disorders measured with the Montreal Cognitive Assessment,” Acta Psychiatrica Scandinavica, vol. 142, no. 5, pp. 413–422, 2020.
[8] C. Mohn and B. R. Rund, “Neurognic function and symptom remission 2 years after ECT in major depressive disorders,” Journal of Affective Disorders, vol. 246, pp. 368–375, 2019.
[9] C. Soraggi-Frez, F. H. Santos, P. B. Albuquerque, and L. F. Malloy-Diniz, “Disentangling working memory functioning in mood states of bipolar disorder: a systematic review,” Frontiers in Psychology, vol. 8, p. 574, 2017.
[10] R. S. Keefe, K. H. Fox, V. G. Davis et al., “The Brief Assessment of Cognition In Affective Disorders (BAC-A):performance of patients with bipolar depression and healthy controls,” Journal of Affective Disorders, vol. 166, pp. 86–92, 2014.
[11] K. E. Burdick, T. E. Goldberg, B. A. Cornblatt et al., “The MATRICS consensus cognitive battery in patients with bipolar I disorder,” Neuropsychopharmacology, vol. 36, no. 8, pp. 1587–1592, 2011.
[12] M. M. Kurtz and R. T. Gerraty, “A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state,” Neuropsychology, vol. 23, no. 5, pp. 551–562, 2009.
[13] F. Franz, “Risk and efficacy in cognitive functions in bipolar disorder II with atypical antipsychotic augmentation,” Psychiatry Danubina, vol. 28, Suppl-1, pp. 13–17, 2016.
[14] J. V. Streicher, H. Wen, T. J. Blom et al., “A preliminary study of the effects of treatment with lithium versus quetiapine on attention of adolescents with bipolar disorder,” Journal of
[15] A. Pigoni, G. M. Mandolini, G. Delvecchio, C. Bressi, J. C. Soares, and P. Brambilla, “A focus on valproate and cognitive deficits in bipolar disorders: a mini-review,” Journal of Affective Disorders, vol. 261, pp. 277–281, 2020.

[16] R. S. Keefe, P. D. Harvey, T. E. Goldberg et al., “Norms and standardization of the brief assessment of cognition in schizophrenia (BACS),” Schizophrenia Research, vol. 102, no. 1-3, pp. 108–115, 2008.